Müllerian inhibiting substance type 2 receptor (MISIIR)-specific CAR T cells for the treatment of ovarian cancer and other gynecologic malignancies
AssigneeThe Trustees of the University of Pennsylvania
InventorsDaniel J. Powell, Alba Rodriguez-Garcia
Life of this patent
Estimating the term…
Abstract
The present disclosure provides modified immune cells or precursors thereof (e.g., modified T cells) comprising a chimeric antigen receptor (CAR) having affinity for Müllerian inhibiting substance type 2 receptor (MISIIR). Compositions and methods of treatment of diseases and disorders, such as ovarian and other gynecologic cancers, are also provided. Additionally provided herein are modified immune cells or precursor cells thereof comprising a nucleic acid encoding a CAR having affinity for Müllerian inhibiting substance type 2 receptor (MISIIR).
Claims5
A modified immune cell or precursor cell thereof, comprising:
- a chimeric antigen receptor (CAR), wherein the CAR comprises an antigen binding domain having affinity for Müllerian inhibiting substance type 2 receptor (MISIIR), a transmembrane domain, and an intracellular domain,
- wherein the CAR comprises the amino acid sequence set forth in SEQ ID NO:
- 2, and/or is encoded by the nucleotide sequence set forth in SEQ ID NO:
- 1.
A method of treating a cancer in a subject in need thereof, comprising administering to the subject a modified T cell comprising:
- a chimeric antigen receptor (CAR), wherein the CAR comprises an antigen binding domain having affinity for Mullerian inhibiting substance type 2 receptor (MISIIR), a transmembrane domain, and an intracellular domain, wherein the CAR comprises the amino acid sequence set forth in SEQ ID NO:
- 2, and/or is encoded by the nucleotide sequence set forth in SEQ ID NO:
- 1.
Dependencies are inferred from the claim text.